Clinical Trial Update: Venetoclax and Azacitidine for the Treatment of High-Risk Recurrent or Refractory Myelodysplastic Syndrome [Phase 1, Phase 2]

View source ↗

Summary

A phase 1/2 clinical trial testing venetoclax in combination with azacitidine for high-risk recurrent or refractory myelodysplastic syndrome has been terminated…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelodysplastic Syndrome
• Myelomonocytic Leukemia
• Therapy-related Myelodysplastic Syndrome

Drugs mentioned

• AZACITIDINE (AZACITIDINE)
• Venetoclax (venetoclax)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome | Phase 1, Phase 2 | Status: TERMINATED